フォローフィードコミュニティでトレーダーや投資家とつながりましょう.
包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.
ターミナル モニターで株式と資産のウォッチリストを整理および監視します
AstraZeneca PLC 02 January 2024 2 January 2024 15:00 GMT Transparency Directive Voting rights and capital The following notification is made in...
AstraZeneca PLC 27 December 2023 27 December 2023 AstraZeneca to acquire Gracell, furthering cell therapy ambition across oncology and autoimmune...
AstraZeneca PLC 22 December 2023 22 December 2023 Wainua (eplontersen) granted first-ever regulatory approval in the US for the treatment of...
AstraZeneca PLC 14 December 2023 14 December 2023 15:00 GMT Transaction by Person Discharging Managerial Responsibilities AstraZeneca PLC (the...
AstraZeneca PLC 12 December 2023 News Release Regulatory News Service 12 December 2023 AstraZeneca to acquire Icosavax, including potential...
AstraZeneca PLC 01 December 2023 1 December 2023 15:05 GMT BLOCK LISTING SIX MONTHLY RETURN Information provided on this form must be typed or...
AstraZeneca PLC 01 December 2023 1 December 2023 15:00 GMT Transparency Directive Voting rights and capital The following notification is made in...
AstraZeneca PLC 01 December 2023 1 December 2023 Update on CRYSTALIZE evidence trials Discontinuation of STABILIZE-CKD and DIALIZE-Outcomes Phase...
AstraZeneca PLC 23 November 2023 23 November 15:00 GMT Transaction by Person Discharging Managerial Responsibilities AstraZeneca PLC (the Company...
AstraZeneca PLC 17 November 2023 17 November 2023 Truqap (capivasertib) plus Faslodex approved in the US for patients with advanced HR-positive...
AstraZeneca PLC 14 November 2023 14 November 2023 Update on PACIFIC-2 Phase III trial of Imfinzi concurrently administered with platinum-based...
AstraZeneca PLC 09 November 2023 9 November 2023 15:00 BST Director Declaration AstraZeneca PLC (the Company) today announced that Philip...
AstraZeneca PLC 09 November 2023 09 November 2023 Imfinzi plus bevacizumab met primary endpoint for progression-free survival in liver cancer...
AstraZeneca PLC 09 November 2023 09 November 2023 AstraZeneca licenses novel agent for the treatment of cardiometabolic conditions and obesity...
AstraZeneca PLC 09 November 2023 AstraZeneca 9 November 2023 9M and Q3 2023 results Strong momentum in the year to date leads to increased...
ご覧いただいた銘柄が下記のボックス内に表示されますので、過去閲覧した銘柄情報に簡単にアクセスすることができます。
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約